Express News | Mind Medicine Shares Are Trading Higher. HC Wainwright & Co. Reiterated a Buy Rating on the Stock
Mind Medicine Analyst Ratings
Optimistic Outlook for Mind Medicine Amidst Promising Phase 3 Developments and Robust Financial Health
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Express News | Mind Medicine Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
Mind Medicine's Strategic Advancements and Clinical Progress Drive Buy Rating
CCORF Maintains Mind Medicine(MNMD.US) With Buy Rating, Raises Target Price to $16
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Cuts Target Price to $21
RBC Capital Keeps Their Buy Rating on Mind Medicine (MNMD)
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)
Express News | Mind Medicine (MindMed) Inc : RBC Raises Target Price to $21 From $20
Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript Summary
Mind Medicine's Financial Health and Phase 3 Progress
10-Q: Quarterly report
Mind Medicine Q3 2024 GAAP EPS $(0.27) Beats $(0.28) Estimate
Mind Medicine GAAP EPS of -$0.27 Beats by $0.03
Express News | MindMed Q3 Net Income USD -13.684 Million
Massachusetts Psychedelics Legalization Initiative Poised to Fail
No Data
No Data